Don't You See Our Shining Faces? HAART's First Decade in Namibia by Callaghan, M
Insight	  Magazine	  (Namibia)	  
November	  2014	  Mike	  Callaghan	  
	  
Don’t	  You	  See	  Our	  Shining	  Faces?	  HAART’s	  first	  decade	  in	  Namibia	  	  	  	   There	  was	  a	  brief	  period	  in	  the	  1990s	  when	  Namibians	  might	  have	  thought,	  however	  briefly,	  that	  they	   would	   escape	   the	   horrors	   of	   the	   new	   plague	   sweeping	   the	   continent.	   	   Richard	   Lee,	   the	   famous	  ethnographer	   of	   the	   Kalahari,	   recounts	   a	   chilling	   story	   of	   sitting	   under	   a	   tree	   with	   a	   group	   of	   San,	  listening	  as	  a	  visiting	  doctor	  anxiously	  tried	  to	  explain	  a	  perplexing	  new	  disease	  known	  in	  the	  big	  city	  as	  “AIDS.”	   	   Those	   innocent	   days	   now	   lie	   on	   the	   far	   side	   of	   a	   complacent,	   slow,	   and	   at	   first	   ineffective	  response	  that	  allowed	  HIV	  to	  gain	  a	  foothold;	  by	  2002	  Namibia’s	  rate	  had	  skyrocketed	  to	  22%:	  the	  fifth-­‐highest	  on	  earth.	  	  There	  are	  several	  theories	  to	  explain	  why	  HIV	  hit	  Namibia	  so	  hard:	  low	  rates	  of	  circumcision,	  high	  rates	   of	   synergistic	   diseases	   like	   tuberculosis,	   busy	   shipping	   and	   trade	   routes;	   it	   also	   seems	   that	   the	  particular	  strain	  of	  HIV	  most	  common	  here	  is	  uniquely	  aggressive	  and	  contagious.	  	  Still,	  it	  is	  hard	  to	  avoid	  the	  conclusion	  that	   the	  government	  response	  allowed	  the	  epidemic	   to	  grow	  larger	  and	  deadlier	   than	   it	  should.	  	  	  Fortunately,	  Namibia’s	  subsequent	  response	  has	  been	  singularly	  effective:	  since	  2003	  the	  MOHSS	  and	   its	   international	   partners	   have	   extended	   life-­‐saving	   anti-­‐retroviral	   drugs	   to	   nearly	   all	   eligible	  patients.	   	   Indeed,	   Namibia	   today	   is	   matched	   only	   by	   Botswana	   and	   Rwanda,	   continent-­‐wide,	   as	   an	  exemplar	  of	  a	  fast	  and	  efficient	  treatment	  rollout.	  	  	  It	  is	  for	  this	  reason	  that	  Namibia	  offers	  a	  compelling	  glimpse	  of	  the	  future	  of	  HIV	  in	  Africa.	  	  After	  a	  decade	   of	   experience,	   this	   country’s	   treatment	   program	   is	   a	   generation	   ahead	   of	   many	   others;	   the	  problems	  of	  Windhoek	  today	  are	  those	  of	  Lusaka	  next	  year,	  and	  Walvis	  Bay’s	  challenges	  tomorrow	  will	  be	  those	  of	  Mombasa	  after	  that.	  	  	  The	  lessons	  that	  Namibia	  holds,	  however,	  are	  surprising.	  	  It	  turns	  out	  that	  long-­‐term,	  large-­‐scale,	  public-­‐sector	   drug	   rollout	   comes	  with	  many	   success	   and	   some	   challenges,	   but	   not	   the	   ones	  we	  might	  expect.	  	  	  
Inputs	  Perhaps	  most	  surprising	  has	  been	  the	  emerging	  evidence	  that	  it	  is	  women	  who	  benefit	  most	  of	  all	  from	  HIV	  treatment.	   	  Along	  the	  ‘HIV	  pipeline’	  from	  testing	  through	  care	  and	  treatment,	  men	  lag	  behind.	  My	  own	  research	  in	  Namibia	  confirms	  that	  women	  outnumber	  men	  in	  testing;	  even	  when	  accounting	  for	  differences	  in	  infection	  rates,	  women	  also	  outnumber	  men	  in	  treatment.	   	  In	  countless	  studies,	  the	  same	  findings	  have	  been	  reported	  across	  sub-­‐Saharan	  Africa.	  	  	  	   In	  my	  own	  research,	  I	  found	  that	  men	  were	  significantly	  more	  sick	  than	  women	  when	  they	  started	  treatment,	  with	  CD4	  counts	  at	   least	  40	  points	   lower;	   this	   is,	   again,	   the	   case	   in	  other	  African	   countries.	  	  
Anecdotally,	  many	  doctors	  report	  than	  by	  the	  time	  some	  men	  finally	  arrive	  at	  the	  clinic,	  their	  disease	  is	  so	  advanced	  there	  is	  little	  to	  be	  done	  for	  them.	  	  	  	   These	   anecdotal	   reports	   are	   supported	   by	  my	   research	   showing	   that	  men	  were	   over	   six	   times	  more	  likely	  than	  women	  to	  die	  after	  entering	  care,	  but	  before	  starting	  medication.	   	  This	  waiting	  period	  seems	  an	  especially	  dangerous	  one	  for	  men,	  and	  indicates	  some	  crucial	  stages	  in	  the	  pipeline	  that	  need	  extra	  attention.	  	  	  One	  reason	  that	  women	  seem	  able	   to	  enter	  care	  sooner	  and	  more	  often	   is	  because	  of	  Namibia’s	  maternity	   system:	  many	  women	   discover	   they	   are	  HIV-­‐positive	   through	   routine	   antenatal	   blood	   tests,	  and	   are	   automatically	   streamed	   into	   the	   treatment	   system.	   	   Motherhood	   is	   so	   culturally	   valued	   and	  supported	  that	  maternity	  can	  be	  an	  ideal	  introduction	  to	  care.	  	  Men	  have	  no	  such	  entry	  point.	  	   Women	  are	  still	  disadvantaged	  in	  many	  spheres	  of	  Namibian	  public	  and	  private	  life;	  it	  seems	  the	  clinic	  floor	  is	  not	  one	  of	  them.	  Men	  urgently	  need	  a	  shift	  in	  gender	  roles	  and	  a	  new,	  ‘value-­‐neutral’	  way	  to	  enter	  testing	  and	  treatment.	  Some	  years	  ago	  I	  sat	  with	  a	  veteran	  HIV	  expert	  in	  Windhoek	  to	  ask	  about	  this	  problem.	  	  Over	  a	  long	  cup	  of	  tea	  he	  explained	  with	  a	  sigh	  the	  frustrations	  he	  had	  experienced	  in	  trying	  to	  attract	  more	  men	  to	  participate	  in	  HIV	  programs.	  	  	  The	  breakthrough,	  for	  him,	  came	  from	  recognizing	  the	  basic	  humanity	  of	  his	  target	  audience:	  just	  because	  they	  are	  unemployed,	  men	  shouldn’t	  be	  expected	  to	  enjoy	  this	  fact	  or	  broadcast	  it	  to	  others,	  but	  this	   is	  exactly	  what	  many	  AIDS	  activities	  require.	   	  By	  respecting	  mens’	  dignity	  and	  scheduling	  outreach	  sessions	  outside	  of	  work	  hours,	  my	  friend	  found	  that	  men	  turned	  out	  in	  droves:	  “you	  plan	  for	  40,”	  he	  said,	  “and	  you	  get	  400.”	  	  
Outcomes	  	   When	  we	  consider	  treatment	  outcomes,	  the	  results	  are	  again	  unintuitive.	  	  In	  the	  early	  days	  of	  drug	  rollout,	  many	   observers	  were	   sceptical.	   	   As	   it	   turns	   out,	   several	   studies	   have	   proven	   programs	   across	  Africa	  are	  capable	  of	  excellent	  results;	  they	  also	  consistently	  show	  that	  men	  here	  have	  poorer	  outcomes	  than	  women.	  	   In	  Walvis	  Bay,	  I	  found	  that	  men	  were	  about	  1.7	  times	  more	  likely	  than	  women	  to	  ‘default’	  –	  that	  is,	  to	   fail	   to	   arrive	   for	   three	  months	   of	   follow-­‐up	   appointments.	   	   This	   could	   be	   hiding	   further	   bad	   news:	  researchers	  in	  Mozambique	  and	  Malawi	  who	  tracked	  down	  treatment	  defaulters	  found	  that	  half	  of	  them	  had	  died.	  	  After	  testing	  and	  recruitment,	  retention	  is	  clearly	  a	  problem.	  	  	   And	  at	  the	  end	  of	  that	  treatment	  pipeline?	  	  Men	  were	  just	  under	  2	  times	  more	  likely	  than	  women	  to	   die	   after	   starting	   treatment.	   Clearly,	   much	   of	   this	   is	   attributable	   to	   men’s	   poorer	   health	   upon	  enrolment,	   and	   their	   higher	   rates	   of	   default.	   	   Still,	   this	   is	   unsatisfying:	   why	   have	   men	   consistently	  benefited	  less	  from	  what	  is	  clearly	  a	  well-­‐run,	  well-­‐publicized	  testing,	  care	  and	  treatment	  program?	  	   There	   are	   no	   simple	   gender	   differences	   in	   physiology	   or	   drug	   metabolism	   that	   explain	   this	  disparity.	   	  The	  explanation	   is	   instead	  a	  complex	  socio-­‐cultural	  and	  political-­‐economic	  one	  that	   involves	  changing	   gender	   roles	   interacting	  with	   the	   health	   system.	   	   Diving	   into	   these	   complexities	   should	   be	   a	  priority.	  	  	  	  
	  
	  
The	  Next	  Generation	  	   Recent	  anecdotal	  evidence	  suggests	   that	  Namibia	  may	  once	  again	  be	  ahead	  of	   the	  curve	  on	   two	  new	  challenges	  for	  the	  next	  generation	  of	  HIV	  treatment.	  	  	  First,	  the	  slow	  and	  inevitable	  emergence	  of	  viruses	  resistant	  to	  antiretroviral	  drugs.	  Normally	  this	  problem	  is	  reduced	  through	  careful	  dosing,	  supporting	  adherence,	  and	  ultimately	  switching	  patients	   to	  different	  pills	  once	  they	  have	   ‘burned	  out’	  their	   last	  combination.	   	  Eventually,	  however,	   the	  options	  are	  exhausted.	  One	  doctor	  working	  in	  HIV	  in	  Walvis	  Bay	  recently	  described	  the	  problem	  to	  me:	  “Resistance,”	  he	  said,	  “is	  going	  to	  be	  a	  big	  problem.	  	  Lately	  I’ve	  seen	  some	  patients	  that	  look	  like	  AIDS	  from	  the	  1990s	  .	  .	  .	  they’re	  drug-­‐resistant	  now,	  and	  the	  old	  opportunistic	  infections	  are	  coming	  back.”	  	  	  Without	  a	  solid	  back	  line	  of	  alternative	  drugs,	  this	  worrying	  development	  threatens	  to	  return	  us	  to	  the	  days	  when	  the	  best	  we	  could	  offer	  AIDS	  patients	  was	  prayers	  and	  painkillers.	  The	  solutions	  here	  are	  not	  easy:	  Namibian	  clinics	  need	  an	  expanded	  capacity	  to	  test	  their	  patients’	  blood	   in-­‐house.	   	   Currently,	   tests	   for	   resistance	   are	   sent	   to	   labs	   in	   South	   Africa.	   	   Further,	   there	   is	   an	  obvious	   need	   for	   more	   and	   better	   antiretroviral	   drugs	   to	   expand	   our	   arsenal.	   	   Without	   a	   domestic	  industry,	  however,	  Namibia	  will	  remain	  at	  the	  mercy	  of	  the	  major	  foreign	  pharmaceutical	  firms.	  The	   second	   new	   development	   is	   a	   reported	   ‘shadow’	   wave	   of	   infections	   among	   school-­‐aged	  children.	  	  In	  interviews,	  several	  Namibian	  HIV	  professionals	  attributed	  this	  to	  various	  things,	  but	  simple	  math	   suggests	   that	   this	   is	   the	   coming	  of	   age	   of	   the	   first	   generation	  of	   children	  born	  during	   the	   ‘boom	  years’	   of	   extremely	   high	  HIV	   prevalence	   in	  Namibia.	   	   These	   observations	   have	   been	   confirmed	   by	   the	  United	   Nations:	   	   they	   reported	   in	   2013	   that	   although	   deaths	   from	   HIV	   worldwide	   are	   down,	   deaths	  among	  children	  10-­‐19	  years	  old	  had	  increased	  dramatically.	  In	   some	   cases	   these	   children	  may	   have	   been	   born	   HIV-­‐positive	   but	   not	   told	   of	   their	   status	   by	  anxious	  parents;	  there	  are	  indeed	  anecdotal	  reports	  of	  children	  believing	  their	  daily	  antiretroviral	  tablets	  were	   “just	  vitamins.”	   	   It	   is	  not	  hard	   to	   sympathize	  with	  a	  parents’	  desire	   to	   shield	   their	   child	   from	  the	  stigma	  of	  HIV.	  	  But	  when	  these	  children	  become	  teens,	  their	  youthful	  romances	  could	  turn	  deadly.	  Young	  people	  are	  notoriously	  difficult	  to	  reach	  with	  HIV	  messaging,	  and	  present	  a	  thorny	  tangle	  of	  legal	   issues	   around	   informed	   consent.	   	   This	   trend	   forces	   us	   to	   acknowledge	   that,	   as	   HIV	   treatment	  extends	  life	  expectancies,	  new	  and	  unimagined	  challenges	  will	  continuously	  emerge.	  	   	  
Conclusions	  If	  truth	  is	  the	  first	  casualty	  of	  war,	  surely	  trust	  is	  the	  first	  casualty	  of	  AIDS.	  	  No	  amount	  of	  tablets	  can	  mend	  broken	  families,	  nor	  has	  the	  rollout	  been	  able	  to	  erase	  the	  heartbreaking	  stigma	  that	  patients	  still	   face	   daily.	   	   The	   offer	   of	   treatment	   is	   also,	   of	   course,	   cold	   comfort	   to	   those	   desperate	   for	  work	   or	  something	  to	  eat.	  	  Still,	  the	  power	  of	  antiretroviral	  therapy	  to	  transform	  HIV	  from	  a	  death	  sentence	  to	  a	  manageable	  chronic	  disease	  is	  little	  short	  of	  miraculous.	  	  All	  we	  have	   learned	  so	   far	   suggests,	   though,	   that	   the	   cost	  of	   antiretroviral	  drugs	  will	  be	  eternal	  vigilance:	  years	  later,	  the	  virus	  still	  has	  the	  power	  to	  surprise	  us.	  	  The	  program	  does	  not	  need	  rescue	  or	  repair,	  but	  constant	  fine-­‐tuning	  to	  ensure	  it	  delivers	  the	  greatest	  benefits	  to	  the	  greatest	  number.	  	   	  This	  fine-­‐tuning	  will	   not	   be	   a	   question	   of	   logistics	   or	   pharmacy,	   but	   anthropology:	  we	   need	   to	   continue	   to	  learn	  about	  the	  complex	  world	  that	  lies	  between	  the	  laboratory	  and	  the	  hands	  of	  patients.	  
Above	   all,	   Namibia’s	   first	   decade	   of	   treatment	   has	   been	   a	   remarkable	   success.	   The	   greatest	  testament	  to	  the	  rollout’s	  efficacy	  is	  the	  patients	  themselves,	  who,	  if	  not	  for	  the	  introduction	  of	  treatment,	  would	  be	   long	  dead.	   	  Four	  years	  ago	   I	   sat	   in	  on	  a	  meeting	  with	  an	  HIV	  support	  group	   in	  Walvis	  Bay.	   I	  asked	   the	  patients	   if	   they	   thought	   the	  government’s	   treatment	  plan	  was	  working.	   	  They	  shrugged,	   and	  looked	  at	  me	  as	  if	  I	  was	  a	  little	  foolish.	  	  Finally,	  one	  of	  the	  women	  took	  a	  slightly	  pitying,	  patient	  tone,	  put	  her	  hand	  on	  my	  shoulder,	  and	  said:	  “don’t	  you	  see	  our	  shining	  faces?”	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